GGHC
PCRX icon

Gilder Gagnon Howe & Co’s Pacira BioSciences PCRX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-217,091
Closed -$8.15M – 304
2017
Q3 		$8.15M Sell
217,091
-825,821
-79% -$33.2M 0.11% 128
2017
Q2 		$49.7M Sell
1,042,912
-181,902
-15% -$8.44M 0.74% 46
2017
Q1 		$55.9M Sell
1,224,814
-1,464
-0.1% -$63.3K 0.94% 31
2016
Q4 		$39.6M Sell
1,226,278
-255,183
-17% -$8.52M 0.78% 42
2016
Q3 		$50.7M Sell
1,481,461
-551,971
-27% -$21.6M 0.87% 36
2016
Q2 		$68.6M Sell
2,033,432
-106,666
-5% -$5.24M 1.36% 17
2016
Q1 		$113M Sell
2,140,098
-75,491
-3% -$4.42M 2.23% 7
2015
Q4 		$170M Buy
2,215,589
+50,865
+2% +$2.88M 2.74% 5
2015
Q3 		$89M Sell
2,164,724
-605,922
-22% -$37.1M 1.41% 18
2015
Q2 		$196M Sell
2,770,646
-108,903
-4% -$8.58M 2.57% 5
2015
Q1 		$256M Sell
2,879,549
-147,178
-5% -$14.9M 3.55% 4
2014
Q4 		$268M Sell
3,026,727
-150,403
-5% -$14.2M 3.99% 2
2014
Q3 		$308M Sell
3,177,130
-96,573
-3% -$9.39M 4.48% 3
2014
Q2 		$301M Sell
3,273,703
-135,329
-4% -$10.3M 3.99% 3
2014
Q1 		$239M Sell
3,409,032
-444,467
-12% -$30.2M 3.25% 3
2013
Q4 		$222M Sell
3,853,499
-157,733
-4% -$8.29M 3.16% 4
2013
Q3 		$193M Sell
4,011,232
-107,533
-3% -$3.92M 3.01% 6
2013
Q2 		$119M Buy
+4,118,765
New +$119M 2.25% 5

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Gilder Gagnon Howe & Co's PCRX Position: Q4 2017 in Review

Gilder Gagnon Howe & Co sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 217,091 shares — an estimated $8.15M sold.

Gilder Gagnon Howe & Co first reported a position in PCRX in Q2 2013 and held it in 18 quarters. The position peaked at $308M in Q3 2014. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Gilder Gagnon Howe & Co reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 217,091 Pacira BioSciences shares in Q4 2017, an estimated $8.15M.
  • Gilder Gagnon Howe & Co first reported a position in Pacira BioSciences in Q2 2013 and held it in 18 quarters.
  • Gilder Gagnon Howe & Co's Pacira BioSciences position peaked at $308M in Q3 2014.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2017, filed 31 Jan 2018.